Valneva - Austrian Visual Worldwide Roadshow 2022

„ Valneva - Advancing Vaccines for Better Lives “

„ Valneva - Disclaimer “

„ Valneva - Summary “

„ Valneva - Research & Development “

„ Valneva - Has An Advanced Clinical Pipeline and Two Approved “

„ Valneva - Lyme Disease Vaccine – VLA15 “

„ Valneva - Lyme Disease Is a Major Health Issue “

„ Valneva - VLA15 – Multivalent Lyme Disease Vaccine Candidate “

„ Valneva - VLA15: Development Progress and Outlook “

„ Valneva - SARS-CoV-2 (COVID-19) Vaccine – VLA2001 “

„ Valneva - VLA2001 – The Only Inactivated Vaccine Against COVID-19 in Clinical Development in Europe “

„ Valneva - Cov-Compare: Head-to-Head vs. AstraZeneca’s Approved COVID-19 Vaccine AZD1222 “

„ Valneva - VLA2001: Statistically More Favorable Tolerability Profile Compared to AZD1222 “

„ Valneva - Co-Primary Immunogenicity Endpoints Met “

„ Valneva - Overall “Cov-Compare Study” Conclusions “

„ Valneva - Positive Topline Homologous Booster Data “

„ Valneva - Current Purchase Agreements and Advanced Discussions “

„ Valneva - VLA2001: Potential to Protect Against Variants “

„ Valneva - VLA2001: Value Growth Through Continuous Extension of Label “

„ Valneva - Chikungunya Vaccine – VLA1553 “

„ Valneva - VLA1553: The Most Advanced Chikungunya Vaccine Candidate “

„ Valneva - VLA1553-301: Positive Topline Phase 3 Results “

„ Valneva - VLA1553: Development Outlook “

„ Valneva - Commercial Products “

„ Valneva - Valneva Has a Specialist Travel Vaccine Business and is a Contractor to the US Military “

„ Valneva - Corporate Highlights and Newsflow “

„ Valneva - VLA Successfully Raised ~ $210 Million in 2021 “

„ Valneva - Key Upcoming Catalysts and Newsflow “

„ Valneva - Thank you “